This is an observational study for women with Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare, lifelong autoimmune disease of the central nervous system, who have been exposed to UPLIZNA® during pregnancy or up to six months before conception. The study aims to understand the safety of UPLIZNA® exposure during pregnancy by tracking the number of newborns with major birth defects, preterm birth, and low birth weight. You can join if you are a woman of reproductive potential with NMOSD who meets the exposure criteria. This study is currently collecting information, but its recruitment status is unclear. No study drug will be given; your healthcare provider will manage your treatment and appointments.

Study design

This is an observational study planning to enroll 60 participants. It is not a randomized trial, meaning participants are not assigned to different treatment groups.

What's involved

This study involves voluntary reporting of pregnancies. Your healthcare provider will determine your office visits and treatment regimens.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for a minimum of 10 years to collect information on newborn outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.